Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Sponsor: Puma Biotechnology, Inc.
Listed as NCT00777101, this PHASE2 trial focuses on Advanced Breast Cancer and Breast Cancer and remains completed. Sponsored by Puma Biotechnology, Inc., it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Puma Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Adelaide, Australia , Aichi, Japan , Alicante, Spain , Amman, Jordan , Ashland, United States , Austin, United States , Badalona, Spain , Bangkok Noi, Thailand , Belgrade, Serbia and 124 more locations